Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director | February 27, 2018 | March 05, 2018 |
| Eledon Pharmaceuticals, Inc.NVUS · Entity 6160 | See Remarks | September 11, 2020 | September 16, 2020 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director | October 01, 2024 | October 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date February 27, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2028-02-27 | Direct | 10,000 |
Reported balance
After 2018-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-27 · Grant · Acquired 10,000 · Balance 10,000 F1: The options vest in three equal (or as close to equal as possible) annual installments, with the first installment to vest on Feb 27, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in three equal (or as close to equal as possible) annual installments, with the first installment to vest on Feb 27, 2019.
Eledon Pharmaceuticals, Inc.
Report date September 11, 2020 · Filed September 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $500.00 · Expires 2030-09-11 | Direct | 2,145.264 |
Reported balance
After 2020-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-11 · Grant · Acquired 2,145.264 · Balance 2,145.264 F1: This option represents a right to purchase a total of 2,145.264 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 1,608.948 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). F2: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 2,145.264 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 1,608.948 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c).
F2: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.
Emmaus Life Sciences, Inc.
Report date October 01, 2024 · Filed October 09, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2020 Filed Sep 16, 2020 00:13 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 2,145.264 | $0.00 Strike: $500.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025170 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,145.264 Underlying: Series X1 Convertible Preferred Stock · 2,145.264 shares Expires 2030-09-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 2,145.264 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 1,608.948 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). F2 · derivative.underlying: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 20:30 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000899243-20-009124 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 26, 2019 Filed Oct 1, 2019 01:30 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-19-024433 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-09-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 60,000 shares of the Issuer's Common Stock, which will vest in equal installments on the first and second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:02 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 1,058 | $1.91 | $2,022.26 |
DisclosureSEC source: 0001562180-19-003052 · primarydocument.xml · nonDerivative · entry 2 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:02 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 4,218 | $1.96 | $8,274.03 |
DisclosureSEC source: 0001562180-19-003052 · primarydocument.xml · nonDerivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,032 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:23 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0000899243-19-008139 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:53 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-18-007648 · doc4.xml · derivative · entry 2 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-03-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 9,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:53 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-007648 · doc4.xml · nonDerivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 5, 2018 15:46 UTC | EMMAUS LIFE SCIENCES, INC. NONE · Entity 156030 | GrantOptions · Derivative | 10,000 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-18-016344 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-27 F1 · derivative.exercise_date: The options vest in three equal (or as close to equal as possible) annual installments, with the first installment to vest on Feb 27, 2019. Read SEC document |
| July 10, 2017 Filed Jul 10, 2017 21:31 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.61 | $0.00 |
DisclosureSEC source: 0000899243-17-018152 · doc4.xml · derivative · entry 1 Kuwahara Jon · CIK 0001664784 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-07-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 7/10/2018, with the remaining 26,250 shares vesting in equal quarterly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.